Paracrine control of steroidogenesis by serotonin in adrenocortical neoplasms

Molecular and Cellular Endocrinology

Volumn 408, Issue , 2015, Pages 198-204

  Lefebvre, H ^a,b   Duparc, C ^a   Prevost G ^a,b   Zennaro, M C ^c   Bertherat, J ^d   Louiset, E ^a  

^a Université de Rouen   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^d INSTITUT COCHIN   (France)

Author keywords

Adrenocortical tumor; Cushing's syndrome; Hyperplasia; Illegitimate receptor; Primary aldosteronism; Serotonin

Indexed keywords

SEROTONIN; STEROID;

ADRENAL CORTEX NEOPLASMS; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; DRUG EFFECTS; HUMAN; HYPERPLASIA; PARACRINE SIGNALING;

ADRENAL CORTEX NEOPLASMS; ANIMALS; HUMANS; HYPERPLASIA; MODELS, BIOLOGICAL; PARACRINE COMMUNICATION; SEROTONIN; STEROIDS;

EID: 84939944215     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.11.013     Document Type: Review

References (65)

1. Ahmed A.H., Calvird M., Gordon R.D., Taylor P.J., Ward G., Pimenta E., et al. Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone/renin ratio in normotensive depressed male patients. J. Clin. Endocrinol. Metab 2011, 96:1039-1045.
2. Bertherat J., Contesse V., Louiset E., Barrande G., Duparc C., Groussin L., et al. In vivo and in vitro screening for illegitimate receptors in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome: identification of two cases of gonadotropin/gastric inhibitory polypeptide-dependent hypercortisolism. J. Clin. Endocrinol. Metab 2005, 90:1302-1310.
3. Beuschlein F., Fassnacht M., Assié G., Calebiro D., Stratakis C.A., Osswald A., et al. Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. N. Engl. J. Med 2014, 370:1019-1028.
4. Bourdeau I., D'Amour P., Hamet P., Boutin J.M., Lacroix A. Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing's syndrome. J. Clin. Endocrinol. Metab 2001, 86:5534-5540.
5. Calogero A.E., Bagdy G., Burrello N., Polosa P., D'Agata R. Role for serotonin3 receptors in the control of adrenocorticotropic hormone release from rat pituitary cell cultures. Eur. J. Endocrinol 1995, 133:251-254.
6. Camilleri M. LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin. Neurogastroenterol. Motil 2011, 23:193-200.
7. Carey R.M., Thorner M.O., Ortt E.M. Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine. J. Clin. Invest 1980, 66:10-18.
8. Cartier D., Lihrmann I., Parmentier F., Bastard C., Bertherat J., Caron P., et al. Overexpression of serotonin4 receptors in cisapride-responsive adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia causing Cushing's syndrome. J. Clin. Endocrinol. Metab 2003, 88:248-254.
9. Cartier D., Jégou S., Parmentier F., Lihrmann I., Louiset E., Kuhn J.-M., et al. Expression profile of serotonin4 (5-HT4) receptors in adrenocortical aldosterone-producing adenomas. Eur. J. Endocrinol 2005, 153:939-947.
10. Chen G.-L., Miller G.M. Advances in tryptophan hydroxylase-2 gene expression regulation: new insights into serotonin-stress interaction and clinical implications. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. Off. Publ. Int. Soc. Psychiatr. Genet 2012, 159B:152-171.
11. Colomb J., Becker G., Forcellini E., Meyer S., Buisson L., Zimmer L., et al. Synthesis and pharmacological evaluation of a new series of radiolabeled ligands for 5-HT7 receptor PET neuroimaging. Nucl. Med. Biol 2014, 41:330-337.
12. Contesse V., Hamel C., Lefebvre H., Dumuis A., Vaudry H., Delarue C. Activation of 5-hydroxytryptamine4 receptors causes calcium influx in adrenocortical cells: involvement of calcium in 5-hydroxytryptamine-induced steroid secretion. Mol. Pharmacol 1996, 49:481-493.
13. Contesse V., Lefebvre H., Lenglet S., Kuhn J.M., Delarue C., Vaudry H. Role of 5-HT in the regulation of the brain-pituitary-adrenal axis: effects of 5-HT on adrenocortical cells. Can. J. Physiol. Pharmacol 2000, 78:967-983.
14. Contesse V., Reznik Y., Duparc C., Perraudin V., Vaudry H., Kuhn J.M., et al. Effects of serotonin and vasopressin on cortisol production from an adrenocortical tumor causing subclinical Cushing's syndrome. Endocr. Res 2002, 28:787-791.
15. Contesse V., Reznik Y., Louiset E., Duparc C., Cartier D., Sicard F., et al. Abnormal sensitivity of cortisol-producing adrenocortical adenomas to serotonin: in vivo and in vitro studies. J. Clin. Endocrinol. Metab 2005, 90:2843-2850.
16. Dall'Asta C., Ballarè E., Mantovani G., Ambrosi B., Spada A., Barbetta L., et al. Assessing the presence of abnormal regulation of cortisol secretion by membrane hormone receptors: in vivo and in vitro studies in patients with functioning and non-functioning adrenal adenoma. Horm. Metab. Res 2004, 36:578-583.
17. Delarue C., Leboulenger F., Morra M., Héry F., Verhofstad A.J., Bérod A., et al. Immunohistochemical and biochemical evidence for the presence of serotonin in amphibian adrenal chromaffin cells. Brain Res 1988, 459:17-26.
18. Duparc, C., Moreau, L., Golib, F., Boulkroun, S., Benecke, A., Gobet, F., etal., 2012. Potential role of intraadrenal mast cells in the physiopathology of aldosterone-producing adenoma, In: ENDO 2012. Presented at the 94th annual meeting of the Endocrine Society, Houston, Texas USA.
19. Feelders R.A., Lamberts S.W.J., Hofland L.J., van Koetsveld P.M., Verhoef-Post M., Themmen A.P.N., et al. Luteinizing hormone (LH)-responsive Cushing's syndrome: the demonstration of LH receptor messenger ribonucleic acid in hyperplastic adrenal cells, which respond to chorionic gonadotropin and serotonin agonists in vitro. J. Clin. Endocrinol. Metab 2003, 88:230-237.
20. Fernandez-Ranvier G.G., Weng J., Yeh R.-F., Khanafshar E., Suh I., Barker C., et al. Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch. Surg. Chic. Ill 1960 2008, 143:841-846.
21. Frishman W.H., Grewall P. Serotonin and the heart. Ann. Med 2000, 32:195-209.
22. Gale, J., Muto, H., Tan, E.F., Allan, R.J., Hidi, R., Prescott, K., 2004. The effect of repeat dosing of mosapride on plasma aldosterone in healthy Japanese volunteers, In: pA2 Online. Presented at the University of Newcastle Winter Meeting, p. 165.
23. 7 receptors. Neuropharmacology 2013, 71:216-227.
24. Gross M.D., Grekin R.J., Gniadek T.C., Villareal J.Z. Suppression of aldosterone by cyproheptadine in idiopathic aldosteronism. N. Engl. J. Med 1981, 305:181-185.
25. Grunenwald, S., Mazzuco, T.L., Mermejo, L.M., Bourdeau, I., Lacroix, A., 2010. In vivo systematic screening for hormone receptors in primary aldosteronism reveals frequent aberrant hormone responsiveness. Presented at the ENDO, p. S1540.
26. Hinson J.P., Vinson G.P., Kapas S., Teja R. The relationship between adrenal vascular events and steroid secretion: the role of mast cells and endothelin. J. Steroid Biochem. Mol. Biol 1991, 40:381-389.
27. Idres S., Delarue C., Lefebvre H., Larcher A., Feuilloley M., Vaudry H. Mechanism of action of serotonin on frog adrenal cortex. J. Steroid Biochem 1989, 34:547-550.
28. Jørgensen H., Knigge U., Kjaer A., Møller M., Warberg J. Serotonergic stimulation of corticotropin-releasing hormone and pro-opiomelanocortin gene expression. J. Neuroendocrinol 2002, 14:788-795.
29. Jørgensen H.S. Studies on the neuroendocrine role of serotonin. Dan. Med. Bull 2007, 54:266-288.
30. Lacroix A., Hamet P., Boutin J.M. Leuprolide acetate therapy in luteinizing hormone - dependent Cushing's syndrome. N. Engl. J. Med 1999, 341:1577-1581.
31. Lacroix A., Bourdeau I., Lampron A., Mazzuco T.L., Tremblay J., Hamet P. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clin. Endocrinol. (Oxf) 2010, 73:1-15.
32. Lampron A., Bourdeau I., Hamet P., Tremblay J., Lacroix A. Whole genome expression profiling of glucose-dependent insulinotropic peptide (GIP)- and adrenocorticotropin-dependent adrenal hyperplasias reveals novel targets for the study of GIP-dependent Cushing's syndrome. J. Clin. Endocrinol. Metab 2006, 91:3611-3618.
33. Lampron A., Bourdeau I., Oble S., Godbout A., Schürch W., Arjane P., et al. Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteronoma. J. Clin. Endocrinol. Metab 2009, 94:750-756.
34. Lefebvre H., Contesse V., Delarue C., Feuilloley M., Hery F., Grise P., et al. Serotonin-induced stimulation of cortisol secretion from human adrenocortical tissue is mediated through activation of a serotonin4 receptor subtype. Neuroscience 1992, 47:999-1007.
35. Lefebvre H., Contesse V., Delarue C., Soubrane C., Legrand A., Kuhn J.M., et al. Effect of the serotonin-4 receptor agonist zacopride on aldosterone secretion from the human adrenal cortex: in vivo and in vitro studies. J. Clin. Endocrinol. Metab 1993, 77:1662-1666.
36. Lefebvre H., Contesse V., Delarue C., Legrand A., Kuhn J.M., Vaudry H., et al. The serotonin-4 receptor agonist cisapride and angiotensin-II exert additive effects on aldosterone secretion in normal man. J. Clin. Endocrinol. Metab 1995, 80:504-507.
37. Lefebvre H., Gonzalez K.N., Contesse V., Delarue C., Vaudry H., Kuhnl J.M. Effect of prolonged administration of the serotonin4 (5-HT4) receptor agonist cisapride on aldosterone secretion in healthy volunteers. Endocr. Res 1998, 24:749-752.
38. Lefebvre H., Cartier D., Duparc C., Contesse V., Lihrmann I., Delarue C., et al. Effect of serotonin4 (5-HT4) receptor agonists on aldosterone secretion in idiopathic hyperaldosteronism. Endocr. Res 2000, 26:583-587.
39. Lefebvre H., Compagnon P., Contesse V., Delarue C., Thuillez C., Vaudry H., et al. Production and metabolism of serotonin (5-HT) by the human adrenal cortex: paracrine stimulation of aldosterone secretion by 5-HT. J. Clin. Endocrinol. Metab 2001, 86:5001-5007.
40. Lefebvre H., Cartier D., Duparc C., Lihrmann I., Contesse V., Delarue C., et al. Characterization of serotonin(4) receptors in adrenocortical aldosterone-producing adenomas: in vivo and in vitro studies. J. Clin. Endocrinol. Metab 2002, 87:1211-1216.
41. Lefebvre H., Prévost G., Louiset E. Autocrine/paracrine regulatory mechanisms in adrenocortical neoplasms responsible for primary adrenal hypercorticism. Eur. J. Endocrinol 2013, 169:R115-R138.
42. Lenglet S., Louiset E., Delarue C., Vaudry H., Contesse V. Activation of 5-HT(7) receptor in rat glomerulosa cells is associated with an increase in adenylyl cyclase activity and calcium influx through T-type calcium channels. Endocrinology 2002, 143:1748-1760.
43. Lim J.E., Porteus C.S., Bernier N.J. Serotonin directly stimulates cortisol secretion from the interrenals in goldfish. Gen. Comp. Endocrinol 2013, 192:246-255.
44. Louiset E., Cartier D., Contesse V., Duparc C., Lihrmann I., Young J., et al. Paradoxical inhibitory effect of serotonin on cortisol production from adrenocortical lesions causing Cushing's syndrome. Endocr. Res 2004, 30:951-954.
45. Louiset E., Contesse V., Groussin L., Cartier D., Duparc C., Barrande G., et al. Expression of serotonin7 receptor and coupling of ectopic receptors to protein kinase A and ionic currents in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome. J. Clin. Endocrinol. Metab 2006, 91:4578-4586.
46. Louiset E., Isvi K., Gasc J.M., Duparc C., Cauliez B., Laquerrière A., et al. Ectopic expression of serotonin7 receptors in an adrenocortical carcinoma co-secreting renin and cortisol. Endocr. Relat. Cancer 2008, 15:1025-1034.
47. Louiset, E., Duparc, C., Renouf, S., Bram, Z., Perraudin, V., Libe, R., etal., 2011. Paracrine regulation of cortisol secretion by serotonin (5-HT) involving illegitimate membrane receptors in primary pigmented nodular adrenal disease (PPNAD). Presented at the ENDO, Boston, Massachusetts, USA, pp. P3-P537.
48. Louiset E., Duparc C., Young J., Renouf S., Tetsi Nomigni M., Boutelet I., et al. Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N. Engl. J. Med 2013, 369:2115-2125.
49. Mannelli M., Ferruzzi P., Luciani P., Crescioli C., Buci L., Corona G., et al. Cushing's syndrome in a patient with bilateral macronodular adrenal hyperplasia responding to cisapride: an in vivo and in vitro study. J. Clin. Endocrinol. Metab 2003, 88:4616-4622.
50. Mantero F., Opocher G., Boscaro M., Armanini D. Effect of serotonin on plasma aldosterone in man. J. Endocrinol. Invest 1982, 5:97-99.
51. Mantero F., Rocco S., Opocher G., Armanini D., Boscaro M., D'Agostino D. Effect of ketanserin in primary aldosteronism. J. Cardiovasc. Pharmacol 1985, 7(Suppl. 7):S172-S175.
52. Marner L., Gillings N., Madsen K., Erritzoe D., Baaré W.F.C., Svarer C., et al. Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET. Neuroimage 2010, 50:855-861.
53. Modlinger R.S., Schonmuller J.M., Arora S.P. Stimulation of aldosterone, renin, and cortisol by tryptophan. J. Clin. Endocrinol. Metab 1979, 48:599-603.
54. Raymond J.R., Mukhin Y.V., Gelasco A., Turner J., Collinsworth G., Gettys T.W., et al. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol. Ther 2001, 92:179-212.
55. Reznik Y., Lefebvre H., Rohmer V., Charbonnel B., Tabarin A., Rodien P., et al. Aberrant adrenal sensitivity to multiple ligands in unilateral incidentaloma with subclinical autonomous cortisol hypersecretion: a prospective clinical study. Clin. Endocrinol. (Oxf.) 2004, 61:311-319.
56. Ritchie P.K., Knight H.H., Ashby M., Judd A.M. Serotonin increases interleukin-6 release and decreases tumor necrosis factor release from rat adrenal zona glomerulosa cells in vitro. Endocrine 1996, 5:291-297.
57. Rittenhouse P.A., Bakkum E.A., Levy A.D., Li Q., Yracheta J.M., Kunimoto K., et al. Central stimulation of renin secretion through serotonergic, noncardiovascular mechanisms. Neuroendocrinology 1994, 60:205-214.
58. Saphier D., Farrar G.E., Welch J.E. Differential inhibition of stress-induced adrenocortical responses by 5-HT1A agonists and by 5-HT2 and 5-HT3 antagonists. Psychoneuroendocrinology 1995, 20:239-257.
59. Schüle C. Neuroendocrinological mechanisms of actions of antidepressant drugs. J. Neuroendocrinol 2007, 19:213-226.
60. Siddiqui E.J., Thompson C.S., Mikhailidis D.P., Mumtaz F.H. The role of serotonin in tumour growth (review). Oncol. Rep 2005, 14:1593-1597.
61. Stergiopoulos S.G., Stratakis C.A. Human tumors associated with Carney complex and germline PRKAR1A mutations: a protein kinase A disease!. FEBS Lett 2003, 546:59-64.
62. Williams T.A., Monticone S., Morello F., Liew C.-C., Mengozzi G., Pilon C., et al. Teratocarcinoma-derived growth factor-1 is upregulated in aldosterone-producing adenomas and increases aldosterone secretion and inhibits apoptosis in vitro. Hypertension 2010, 55:1468-1475.
63. Ye P., Mariniello B., Mantero F., Shibata H., Rainey W.E. G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism. J. Endocrinol 2007, 195:39-48.
64. Zimmer L., Le Bars D. Current status of positron emission tomography radiotracers for serotonin receptors in humans. J. Label. Compd Radiopharm 2013, 56:105-113.
65. Zwermann O., Suttmann Y., Bidlingmaier M., Beuschlein F., Reincke M. Screening for membrane hormone receptor expression in primary aldosteronism. Eur. J. Endocrinol 2009, 160:443-451.